ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia
Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to... | March 30, 2023
United States Christopheru Missling Andrewj Barwicki Parkinson Progression Markers Initiative Cohort Company Nasdaq Research Business Development
Source: marketscreener.com